Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung
Department of Oncology, St. Claraspital, Kleinriehenstrasse 30, Basel 4016, Switzerland
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(3), 217-219; https://doi.org/10.3747/co.25.3936
Submission received: 4 March 2018
/
Revised: 6 April 2018
/
Accepted: 9 May 2018
/
Published: 1 June 2018
Abstract
We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.
Share and Cite
MDPI and ACS Style
Schmid, T.; Buess, M. Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung. Curr. Oncol. 2018, 25, 217-219. https://doi.org/10.3747/co.25.3936
AMA Style
Schmid T, Buess M. Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung. Current Oncology. 2018; 25(3):217-219. https://doi.org/10.3747/co.25.3936
Chicago/Turabian StyleSchmid, T., and M. Buess. 2018. "Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung" Current Oncology 25, no. 3: 217-219. https://doi.org/10.3747/co.25.3936
